The trust aims to provide investors with access to a wide range of opportunities in China, leveraging the unique advantages of its structure, such as the ability to use gearing, invest in private companies, and employ derivatives. I look for firms with scalable growth potential, strong returns on capital based on a clear competitive advantage and strong management.
These often align with secular growth trends, but I pay close attention to cyclicality, as it can also present opportunities. I prioritise management teams with a proven record of strong execution and favour under-researched small- and mid-cap stocks capable of outperforming the market.
Where to invest in China
One company I have invested in is Medlive Technology (Hong Kong: 2192). It operates a leading online platform connecting pharmaceutical and medical device companies with doctors, providing medical information, clinical guidelines, and diagnostic tools.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Its core strength lies in digital healthcare marketing, and it is benefiting from the ongoing shift of healthcare budgets from offline to online channels. Medlive has demonstrated robust growth, with its client base and the number of products promoted rising significantly.
Despite recent anti-corruption crackdowns, the long-term outlook for drug and medical device development in China remains strong, driven by a shift from sales and promotion to increased investment in research and development.
As more new drugs are developed, pharmaceutical companies will require enhanced marketing support. Medlive, with its focus on precision digital marketing, is well-placed to benefit from this transition. With limited competition and ample reinvestment opportunities, Medlive remains a compelling long-term growth story.
Ping An Insurance (Hong Kong: 2318) is one of China’s leading financial services providers, offering a wide range of insurance and investment products. China’s insurance sector remains underpenetrated compared with Western markets, presenting strong long-term growth potential.
Ping An is well positioned to capitalise on this, benefiting from robust demand in life insurance, particularly in elder care and critical illness coverage. It is gaining efficiency through investment in technology and bolstering risk control through better asset-liability management, tighter underwriting standards and improving the sales force’s skills. Meanwhile, the stock is attractively valued at a discount to book value, with strong capital return policies delivering an appealing dividend yield.
Tuhu Car (Hong Kong: 9690) is China’s leading car services provider, leveraging digitalisation to transform customers’ experiences, standardise services, and drive efficiency. The company’s platform integrates booking, parts ordering, service tracking, and technical support, creating a highly scalable, capital-light model.
In a fragmented market dominated by small local players, Tuhu has consolidated its position as the largest player, with over 4,000 franchised stores. China’s ageing car fleet is fuelling demand for maintenance, and Tuhu’s scale – it is one of the world’s largest purchasers of tyres – gives it significant pricing power.
The group also has substantial scope for expanding its margins through private-label products, increasing offline traffic, and enhancing high-value chassis services. The trust first invested in Tuhu as a private company, so I’ve known it for a long time. With few direct rivals and a proven growth strategy, it still stands out as an attractive long-term investment.
This article was first published in MoneyWeek's magazine. Enjoy exclusive early access to news, opinion and analysis from our team of financial experts with a MoneyWeek subscription.
-
Starling Bank under fire after customers rejected for new savings accountMoneyWeek investigates why some Starling Bank customers are being rejected for its recently launched easy-access savings account
-
UK house prices rose 3.3% over past 12 months - what’s in store for 2025?The Land Registry house price index reveals annual inflation of 3.3%, with the average property price reaching £290,000 in November. Will house prices continue to increase this year?
-
How to find top-quality companies with sustainable and growing dividendsIan Mortimer, portfolio manager of Guinness Global Equity Income Fund, shares where he would put his money for sustainable and growing dividends
-
Chinese stocks slump on first trading day of 2025Chinese stocks suffered in the new year from their worst first day of trading since 2016, despite a state stimulus package
-
Three British stocks boasting reliable and growing dividendsRebecca Maclean, co-manager of Dunedin Income Growth Investment Trust, highlights three British stocks worth investing in
-
Where to invest – MoneyWeek writers give their tipsInvest in Canada and US small caps, and snap up a cosmetics company and a Hungarian telecoms outfit
-
MoneyWeek's trading tips - how did they fare in 2024?My tips have yielded a profit and the open positions are proving lucrative, too
-
Share buybacks rise in the UK – what effect will it have?Share buybacks are gaining popularity in the UK – good news for investors
-
Should you bet on US stocks?You don’t have to be bearish on US stocks to worry that they are now such a large share of global indices
-
Is now the time to buy Marshalls?Former market darling Marshalls, a landscaping and building products supplier, looks too cheap. Is it time to buy this once-admired stock?
